Skip to main content
Cureus logoLink to Cureus
. 2022 May 20;14(5):e25157. doi: 10.7759/cureus.25157

The Influence of Obesity Hypoventilation Syndrome on the Outcomes of Patients With Diabetic Ketoacidosis

Meghana Pattipati 1,, Goutham Gudavalli 2, Lohitha Dhulipalla 1
Editors: Alexander Muacevic, John R Adler
PMCID: PMC9205449  PMID: 35733497

Abstract

Purpose: The effect of comorbid obesity hypoventilation syndrome (OHS) on hospitalized patients with diabetic ketoacidosis (DKA) has not been studied so far. This study elucidates the outcomes of DKA patients with OHS compared to those without OHS.

Methods: Patients above 18 years of age were included in the study. The National Inpatient Sample (NIS) database of 2017 and 2018 was used and data were extracted using the International Classification of Diseases, Tenth Revision (ICD-10) codes; OHS ICD-10 code being “E66.2” and DKA ICD-10 codes being “E08.1, E09.1, E10.1, E11.1, and E13.1.” The comorbid medical conditions were also identified using the ICD-10 codes. Logistic regression analysis was performed to examine the impact of OHS on in-hospital outcomes of DKA patients.

Results: OHS was prevalent in 0.61% of the general population, as per the NIS database in the years 2017 and 2018. Primary outcomes of the study were in-hospital mortality, whereas secondary outcomes included acute kidney failure, the requirement for invasive mechanical ventilation, length of stay, and cost of hospitalization. OHS in DKA patients was associated with increased mortality (odds ratio (OR): 4.35 (2.63-7.20), p < 0.00001; adjusted OR (aOR): 1.79 (1.01-3.15), p < 0.044), acute kidney failure (OR: 2.44 (1.79-3.33), p < 0.00001; aOR: 1.43 (1.03-2.00), p < 0.031), invasive mechanical ventilation (OR: 4.17 (2.90-5.98), p < 0.00001; aOR: 1.62 (1.08-2.41), p < 0.017), increased length of stay (10.02 ± 12.42 vs. 4.70 ± 6.31, p < 0.00001), and cost of care (132314 ± 197111.8 vs. 54245.06 ± 98079.89, p < 0.00001). All-cause mortality of patients with DKA and OHS using the Cox proportional hazards ratio was 1.70 (1.02-2.84, p < 0.024) after adjusting for age, race, sex, smoking, obesity, and comorbidities such as heart failure, hypertension, chronic obstructive pulmonary disease, chronic ischemic heart disease, chronic kidney disease, liver disease, and cerebral infarction.

Conclusion: OHS is an independent risk factor for mortality in DKA, irrespective of the degree of obesity. Further prospective studies are recommended to study the effects of different treatment modalities of OHS such as identification of the need for early non-invasive ventilation or for early invasive mechanical ventilation to improve outcomes in DKA patients.

Keywords: diabetic ketoacidosis, diabetes, obesity hypoventilation syndrome, osa, obesity

Introduction

Obesity is a major risk factor for diabetes. Diabetic ketoacidosis (DKA) is commonly seen in patients with type 1 diabetes mellitus. According to a study in recent years, an increasing incidence of DKA has been reported without a precipitating cause, especially in people of all age groups with type 2 diabetes. These subjects are usually obese and have a strong family history of diabetes. These subjects are usually referred to as patients with Flatbush diabetes and ketosis-prone type 2 diabetes [1]. Obesity also predisposes patients to obesity hypoventilation syndrome (OHS), which is defined as obesity (BMI ≥ 30) and chronic alveolar hypoventilation leading to daytime hypercapnia and hypoxia (partial pressure of carbon dioxide ≥ 45 and partial pressure of oxygen < 70 mmHg) and sleep-disordered breathing in the absence of significant lung or respiratory muscle disease [2]. The morbidity and mortality are high for patients with OHS [2]. Patients with OHS are more likely to be diagnosed with congestive heart failure, angina pectoris, and cor pulmonale and are at a higher risk for admission to ICU and invasive mechanical ventilation than the population with a similar degree of obesity without hypoventilation. Prevalence of obesity is increasing overall and is 20% in ICU patients [3]. Obesity is associated with an increased risk of acute kidney injury (AKI) [3]. The impact of obesity on ICU mortality is debated [3]. DKA is an acute life-threatening complication of diabetes, leading to severe electrolyte abnormalities and dehydration, if not corrected in a timely fashion, leading to adverse outcomes. The aim of this study is to improve our understanding of the influence of OHS on the outcomes in patients admitted with DKA. There are no prior studies done on patients with OHS and DKA.

Materials and methods

Data source

We utilized the Agency for Healthcare Research and Quality's (AHRQ) National Inpatient Sample (NIS) database, which is developed as part of the Healthcare Cost and Utilization Project (HCUP). NIS is the largest all-payer inpatient healthcare database in the United States. It includes data from approximately 7 million patient hospital stays per year from over 1,000 hospitals and is a representative sample of about 20% of non-federal hospitals in the United States.

Patient population

The aim of this study is to improve our understanding of the factors that influence the outcomes of DKA patients with underlying OHS in comparison with DKA patients without OHS. This is a retrospective cohort study of the NIS database, which includes the years 2017 and 2018. The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for both DKA and OHS is used. All patients above the age of 18 years with the diagnosis of DKA were extracted using the International Classification of Diseases, Tenth Revision (ICD-10) codes “E08.1, E09.1, E10.1, E11.1, and E13.1” and included in the study. Patients with OHS are identified using the ICD-10 diagnostic code “E66.2.” Baseline demographics and social variables such as age, gender, race, smoking history, various comorbidities (hypertension, obesity, liver disease, chronic lung disease, chronic kidney disease (CKD), cerebral infarction, heart failure, atrial fibrillation and atrial flutter, chronic ischemic heart disease, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), and BMI), and social factors like insurance payer, hospital bed size, socioeconomic status based on household income, location, region of the hospital, and teaching status were included in the analysis.

Statistical analysis

The primary outcome of the study is to estimate in-hospital mortality. Secondary outcomes of interest are acute respiratory failure, acute kidney failure, length of stay, need for mechanical ventilation, and cost of care during hospitalization. Multivariate logistic regression is used to adjust for potential confounders including age, gender, race, smoking, heart failure, COPD, hypertension, obesity, atrial fibrillation and atrial flutter, CKD, chronic liver disease, cerebral infarction, ischemic heart disease, and socioeconomic status. STATA/SE version 17.0 (StataCorp LLC, College Station, TX) is used for the analysis of the data.

Results

In the years 2017 and 2018, the total hospitalizations with a primary diagnosis of DKA were 60,607 and the concomitant diagnoses of OHS were 172. The mean age of patients without OHS was 45.4 ± 17.8 years (range: 18-90 years) and the mean age of patients with OHS was 56.25 ± 13.47 years (range: 23-90 years) (p < 0.0001). Patients with OHS are relatively older at the time of admission. Table 1 describes the baseline demographics of the patients admitted with DKA with and without OHS. Approximately 57-65% of the patients were Caucasians in both groups. In the OHS group, there were more females than those in the without OHS group (55% vs. 49.5%, p < 0.132); however, it was not statistically significant. Greater number of patients in the OHS group had comorbidities such as hypertension (84% vs. 52%, p < 0.00001), heart failure (50% vs. 9.4%, p < 0.0001), atrial fibrillation and atrial flutter (25.6% vs. 6.2%, p < 0.00001), COPD (32.6% vs. 7.4%, p < 0.00001), OSA (15.7% vs. 3.7%, p < 0.00001), CKD (38.4% vs. 17.7%, p < 0.00001), liver disease (14.5% vs. 6%, p < 0.00001), cerebral infarction (4% vs. 1.5%, p < 0.0052), chronic ischemic heart disease (22.1% vs. 13.5%, p < 0.0009), and BMI between 30 and 40 (15.12% vs. 6.2%, p < 0.00001) and BMI ≥ 40 (70.35% vs. 4.5%, p < 0.00001).

Table 1. Baseline demographics and comorbidities in patients admitted with diabetic ketoacidosis (DKA) (n = 60,607) with and without obesity hypoventilation syndrome (OHS).

COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; LOS, length of stay.

Variables DKA without OHS (n = 60,435) Percentage (%) DKA with OHS (n = 172) Percentage (%) P-value
Sex          
Male 30,517 50.5% 77 44.77% p < 0.133
Female 29,912 49.5% 95 55.23% p < 0.132
Age group          
≥18 to <20 2,398 3.97% 0 0 -
≥20 to <30 12,556 20.78% 7 4.07% p < 0.001
≥30 to <40 10,352 17.13% 16 9.30% p < 0.006
≥40 to <50 10,018 16.58% 25 14.53% p < 0.472
≥50 to <60 10,809 17.89% 46 26.74% p < 0.002
≥60 to <70 7,929 13.12% 54 31.40% p < 0.001
≥70 to <80 4,343 7.19% 21 12.21% p < 0.010
≥80 to <90 1,726 2.86% 2 1.16% p < 0.182
≥90 304 0.50% 1 0.58% p < 0.884
Mean age 45.40 ± 17.83   56.25 ± 13.47    p < 0.001
Race          
White 33,956 57.44% 111 65.29% p < 0.027
Black 14,395 24.35% 38 38 p < 0.596
Hispanic 7,675 12.98% 15 15 p < 0.117
Asian/Pacific Island 924 1.56% 0 0 -
Native American 608 1.03% 1.03% 2 p < 0.837
Other 1,557 2.63% 2.63% 4 p < 0.836
Pay          
Medicare 17,295 28.66% 84 49.12% p < 0.001
Medicaid 18,556 30.75% 46 26.90% p < 0.261
Private insurance 15,676 25.98% 30 17.54% p < 0.011
Self-pay 6,686 11.08% 7 4.09% p < 0.003
No charge 479 0.79% 0 0 -
Other 1,654 2.74% 4 2.34% p < 0.741
Household income          
0 to 25th percentile 21,943 37.09% 61 36.09% p < 0.818
26th to 50th percentile 16,777 28.36% 56 33.14% p < 0.160
51st to 75th percentile 12,544 21.20% 33 19.53% p < 0.612
76th to 100th percentile 7,899 13.35% 19 11.24% p < 0.431
Smoking 15,721 26% 27 15.7% p < 0.002
Bed size          
Small 13,527 22.38% 30 17.44% p < 0.120
Medium 18,154 30.04% 48 29.91% p < 0.542
Large 28,754 47.58% 94 54.65% p < 0.063
Location of hospital/teaching status          
Rural 6,526 10.80% 11 6.40% p < 0.063
Urban non-teaching 13,212 21.86% 34 19.77% p < 0.507
Urban teaching 40,697 67.34% 127 73.84% p < 0.069
Hospital region          
Northeast 8,924 14.77% 29 16.86% p < 0.439
Midwest 13,027 21.56% 44 25.58% p < 0.199
South 26,226 43.40% 65 37.79% p < 0.138
West 12,258 20.28% 34 19.97% p < 0.867
Diabetes 60,435 100% 172 100% p < 0.001
Obesity 7,963 13.18% 172 100% p < 0.001
Hypertension 31,486 52.10% 144 83.72% p < 0.001
Heart failure 5,551 9.19% 86 50% p < 0.001
Atrial fibrillation/atrial flutter 3,739 6.19% 44 25.58% p < 0.001
COPD 4,442 7.35% 56 32.56% p < 0.001
CKD 10,712 17.72% 66 38.37% p < 0.001
Liver disease 3,630 6.01% 25 14.53% p < 0.001
Cerebral infarction 897 1.48% 7 4.07% p < 0.005
Chronic ischemic heart disease 8,127 13.45% 38 22.09% p < 0.0009
BMI          
1 (30-40) 3,743 6.19% 26 15.12% p < 0.001
2 (>40) 2,731 4.52% 121 70.35% p < 0.001
Total charges 54245.06 ± 98079.89    132314 ± 197111.8   p < 0.001
LOS 4.70 ± 6.31   10.02 ± 12.42   p < 0.001

Table 2 describes the in-hospital outcomes of patients with DKA and OHS. We observed a significant increase in the in-hospital mortality (odds ratio (OR): 4.35 (2.63-7.20), p < 0.00001; adjusted OR (aOR): 1.79 (1.01-3.15), p < 0.044), acute kidney failure (OR: 2.44 (1.79-3.33), p < 0.00001; aOR: 1.43 (1.03-2.00), p < 0.031), and mechanical ventilation (OR: 4.17 (2.90-5.98), p < 0.00001; aOR: 1.62 (1.08-2.41), p < 0.017) in patients with OHS in comparison to patients without OHS. The length of stay in DKA patients with comorbid OHS was 10.02 ± 12.42, whereas in DKA patients without OHS, it was 4.70 ± 6.31 (p < 0.00001). The cost of care was 132314 ± 197111.8 in DKA patients with OHS vs. 54245.06 ± 98079.89 in DKA patients without OHS (p < 0.00001) (Table 1). Incidence of acute respiratory failure was higher in the OHS group in the unadjusted OR; however, no statistically significant difference was found after adjusting for various variables (OR: 4.089 (2.90-5.75), p < 0.00001; aOR: 1.36 (0.93-2.00), p < 0.106). Both the primary and secondary outcomes are adjusted for age, sex, race, smoking, insurance, and socioeconomic status based on household income, and various comorbidities such as hypertension, obesity, heart failure, COPD, atrial fibrillation and atrial flutter, CKD, cerebral infarction, liver disease, and chronic ischemic heart disease.

Table 2. In-hospital outcomes for patients admitted with diabetic ketoacidosis (n = 60,607) with and without obesity hypoventilation syndrome.

Outcomes Odds ratio P-value  Adjusted odds ratio P-value 
In-hospital mortality 4.35 (2.63-7.20) <0.00001 1.79 (1.01-3.15) <0.044
Acute respiratory failure 4.089 (2.90-5.75) <0.00001 1.36 (0.93-2.00) <0.106
Mechanical ventilation 4.17 (2.90-5.98) <0.00001 1.62 (1.08-2.41) <0.017
Acute kidney failure 2.44 (1.79-3.33) <0.00001 1.43 (1.03-2.00) <0.031

NIS is the largest inpatient database representing >97% of the US population. Utilizing this database, we showed the following significant findings: (1) patient characteristics such as age, smoking, hypertension, heart failure, atrial fibrillation, atrial flutter, OSA, COPD, CKD, liver disease, cerebral infarction, chronic ischemic heart disease, and BMI are significantly different in OHS patients compared to non-OHS patients (p < 0.05). (2) The prevalence of OHS in DKA patients is 0.28%. (3) OHS in DKA patients was associated with increased mortality (OR: 4.35 (2.63-7.20), p < 0.00001; aOR: 1.79 (1.01-3.15), p < 0.044), acute kidney failure (OR: 2.44 (1.79-3.33), p < 0.00001; aOR: 1.43 (1.03-2.00), p < 0.031), and mechanical ventilation (OR: 4.17 (2.90-5.98), p < 0.00001; aOR: 1.62 (1.08-2.41), p < 0.017). (4) OHS in DKA patients is associated with increased length of stay (10.02 ± 12.42 vs. 4.70 ± 6.31, p < 0.00001) and cost of care (132314 ± 197111.8 vs. 54245.06 ± 98079.89, p < 0.00001). (5) All-cause mortality of patients with DKA and OHS calculated using the Cox proportional hazards ratio was 1.70 (1.02-2.84, p < 0.024) after adjusting for age, race, sex, smoking, obesity, and comorbidities such as heart failure, hypertension, COPD, chronic ischemic heart disease, CKD, liver disease, and cerebral infarction. The baseline characteristics revealed no significant difference in males and females in the two groups (the p-value was not statistically significant).

Discussion

The effects of obesity on diabetes and metabolic syndrome are well known. The prevalence of OHS in the general population according to the NIS database in 2017 and 2018 was 0.61%. A condition termed malignant OHS is used to describe a severe multi-system disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity-related hypoventilation together with systemic hypertension, diabetes, metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension, and hepatic dysfunction [4]. Overweight and obesity increase all-cause mortality [5]. OHS as an independent risk factor for mortality in DKA patients has not been studied. Hyperglycemia causes an increase in mortality with an OR of >2.85 in patients with blood glucose > 300 mg/dl [6]. OHS is independently associated with increased mortality, and in the setting of another acute event like DKA, the odds of mortality, the requirement for mechanical ventilation, and acute kidney failure are higher. Our study also showed that the length of stay and cost of hospitalization are much higher in patients with coexistent DKA and OHS.

Outpatient treatment for OHS includes weight loss, bariatric surgery, continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) [7]. OHS is a relatively underdiagnosed medical condition and, if untreated, leads to increased morbidity and mortality and adverse health-related outcomes related to cardiovascular and respiratory complications [8-12]. Diabetes is an independent predictor of mortality in OHS [4]. This study emphasizes that the coexistence of diabetes and OHS could intensify the risk of mortality in acute conditions like DKA. Severe OHS should be treated as a systemic disease with respiratory, metabolic, and cardiovascular components that require a multi-model therapeutic approach [13]. Most OHS patients died from heart failure rather than respiratory failure and obesity did not have any effect on mortality [13].

OHS patients had higher mortality compared to simple obesity, it increases the burden of chronic inflammation, is a pro-inflammatory state, and work of breathing is higher in OHS compared to eucapnic obesity [14]. Diabetes is characterized by increased oxidative stress and endothelial dysfunction, which play a major role in diabetic vascular disease and the risk for complications related to the cardiovascular system [15]. OHS is also characterized by increased oxidative stress and decreased ventilatory drive, a theory correlated to hyperleptinemia, associated with a reduction in respiratory drive and reduced hypercapnia response irrespective of the amount of body fat. As leptin is a stimulant of ventilation, this study suggests an extension of leptin resistance to the respiratory center [16]. Central leptin resistance results in high plasma leptin and increased peripheral actions of leptin such as increased sympathetic outflow and cytokine production, which further contribute to adverse outcomes in DKA [17]. DKA is attributed to relative insulin insufficiency and excess production of stress hormones (glucagon, catecholamine, cortisol, and growth hormone) and results in metabolic acidosis [18]. Metabolic acidosis in DKA is compensated by an increase in the respiratory rate (Kussmaul breathing) and respiratory alkalosis, which is compromised in patients with OHS due to poor breathing, which could lead to adverse outcomes such as the need for invasive mechanical ventilation when they coexist and even respiratory failure. Hence, early recognition of OHS and initiation of NIV could be helpful and further research is necessary based on prospective studies to have a better understanding of the outcomes with the initiation of early vs. late NIV in patients hospitalized with coexisting OHS and DKA.

The study has some limitations. This is a retrospective cross-sectional study done using the NIS database, which cannot draw any conclusions on causal relationships but can strongly point toward any major associations. Data regarding adherence to medications in diabetic patients and compliance with CPAP vs. NIV in OHS are lacking. Duration of disease and lab parameters are not available in the database. Confounding bias can occur due to missing variables despite performing multivariate analysis for as many variables as possible. However, the generalizability of the database to the nation's population is a validated tool. The conclusion of this study is to recognize OHS as a possible comorbidity, and early initiation of NIV or CPAP might improve mortality and prevent mechanical ventilation in patients admitted with DKA.

Conclusions

OHS is an independent risk factor for mortality in DKA, irrespective of the degree of obesity. Further prospective studies are recommended to study the effects of different treatment modalities of OHS such as the identification of the need for early NIV or for early invasive mechanical ventilation to improve outcomes in DKA patients.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study

Animal Ethics

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

References

  • 1.Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Umpierrez GE. Diabetes Care. 2006;29:2755–2757. doi: 10.2337/dc06-1870. [DOI] [PubMed] [Google Scholar]
  • 2.Assessment and management of patients with obesity hypoventilation syndrome. Mokhlesi B, Kryger MH, Grunstein RR. Proc Am Thorac Soc. 2008;5:218–225. doi: 10.1513/pats.200708-122MG. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Obesity in the critically ill: a narrative review. Schetz M, De Jong A, Deane AM, et al. Intensive Care Med. 2019;45:757–769. doi: 10.1007/s00134-019-05594-1. [DOI] [PubMed] [Google Scholar]
  • 4.The malignant obesity hypoventilation syndrome (MOHS) Marik PE. Obes Rev. 2012;13:902–909. doi: 10.1111/j.1467-789X.2012.01014.x. [DOI] [PubMed] [Google Scholar]
  • 5.Body-mass index and mortality among 1.46 million white adults. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. N Engl J Med. 2010;363:2211–2219. doi: 10.1056/NEJMoa1000367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Crit Care Med. 2009;37:3001–3009. doi: 10.1097/CCM.0b013e3181b083f7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Evaluation and management of obesity hypoventilation syndrome. An official American Thoracic Society clinical practice guideline. Mokhlesi B, Masa JF, Brozek JL, et al. Am J Respir Crit Care Med. 2019;200:0–24. doi: 10.1164/rccm.201905-1071ST. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Nowbar S, Burkart KM, Gonzales R, et al. Am J Med. 2004;116:1–7. doi: 10.1016/j.amjmed.2003.08.022. [DOI] [PubMed] [Google Scholar]
  • 9.The use of health-care resources in obesity-hypoventilation syndrome. Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. Chest. 2001;120:377–383. doi: 10.1378/chest.120.2.377. [DOI] [PubMed] [Google Scholar]
  • 10.Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Jennum P, Kjellberg J. Thorax. 2011;66:560–566. doi: 10.1136/thx.2010.143958. [DOI] [PubMed] [Google Scholar]
  • 11.Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Priou P, Hamel JF, Person C, Meslier N, Racineux JL, Urban T, Gagnadoux F. Chest. 2010;138:84–90. doi: 10.1378/chest.09-2472. [DOI] [PubMed] [Google Scholar]
  • 12.In-hospital mortality in the Pickwickian syndrome. Miller A, Granada M. Am J Med. 1974;56:144–150. doi: 10.1016/0002-9343(74)90591-9. [DOI] [PubMed] [Google Scholar]
  • 13.Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, Golpe R, Méndez Marote L, Castro-Castro J, González Quintela A. PLoS One. 2015;10:0. doi: 10.1371/journal.pone.0117808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. Borel JC, Roux-Lombard P, Tamisier R, et al. PLoS One. 2009;4:0. doi: 10.1371/journal.pone.0006733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Endothelial dysfunction in diabetes. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Br J Pharmacol. 2000;130:963–974. doi: 10.1038/sj.bjp.0703393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients. Campo A, Frühbeck G, Zulueta JJ, et al. Eur Respir J. 2007;30:223–231. doi: 10.1183/09031936.00115006. [DOI] [PubMed] [Google Scholar]
  • 17.Adipose tissue, adipokines, and inflammation. Fantuzzi G. J Allergy Clin Immunol. 2005;115:911–919. doi: 10.1016/j.jaci.2005.02.023. [DOI] [PubMed] [Google Scholar]
  • 18.Current concepts of the pathogenesis and management of diabetic ketoacidosis (DKA) Yan P, Cheah JS, Thai AC, Yeo PP. https://pubmed.ncbi.nlm.nih.gov/6331271/ Ann Acad Med Singap. 1983;12:596–605. [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES